 |
 Video: What is a Stock Split?
|
|
|
| ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for woman's reproductive health and pregnancy. Co.'s portfolio includes: Linzagolix, which is an oral gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis in pre-menopausal women; Ebopiprant, which is an oral selective prostaglandin F2a, receptor antagonist, treatment for preterm labor; and Nolasiban, which improves clinical pregnancy and live birth rates in women undergoing embryo transfer following an in-vitro fertilization cycle. According to our OBSV stock split history records, OBSV has had 0 splits. | |
|
OBSV (OBSV) has 0 splits in our OBSV stock split history database.
Looking at the OBSV stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into OBSV shares, starting with a $10,000 purchase of OBSV, presented on a split-history-adjusted basis factoring in the complete OBSV stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
01/27/2017 |
|
| End date: |
03/22/2023 |
|
| Start price/share: |
$11.68 |
|
| End price/share: |
$0.10 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.13% |
|
| Average Annual Total Return: |
-53.75% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$87.32 |
|
| Years: |
6.15 |
|
|
|
|
|
